Search

Your search keyword '"*CANDESARTAN"' showing total 1,316 results

Search Constraints

Start Over You searched for: Descriptor "*CANDESARTAN" Remove constraint Descriptor: "*CANDESARTAN" Topic benzimidazoles Remove constraint Topic: benzimidazoles
1,316 results on '"*CANDESARTAN"'

Search Results

1. Achieved dose and treatment discontinuation of candesartan in men and women with chronic heart failure: data from CHARM.

2. Telmisartan and candesartan promote browning of white adipose tissue and reverse fatty liver changes in high fat diet fed male albino rats.

3. Candesartan upregulates angiotensin-converting enzyme 2 in kidneys of male animals by decreased ubiquitination.

4. Candesartan Attenuates Vasculitis in a Mouse Model of Kawasaki Disease Induced by Candida albicans Water-Soluble Fraction.

5. Candesartan protects against d-galactose induced - Neurotoxicity and memory deficit via modulation of autophagy and oxidative stress.

6. Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage.

7. Low-dose candesartan prevents schizophrenia-like behavioral alterations in a neurodevelopmental two-hit model of schizophrenia.

8. Physiologically based pharmacokinetic modeling of candesartan related to CYP2C9 genetic polymorphism in adult and pediatric patients.

9. Genetic variants of GRK4 influence circadian rhythm of blood pressure and response to candesartan in hypertensive patients.

10. Secondary Effects of Hypochlorite Treatment on the Emerging Pollutant Candesartan: The Formation of Degradation Byproducts and Their Toxicological Profiles.

11. Study of Neuroprotection by a Combination of the Biological Antioxidant ( Eucalyptus Extract) and the Antihypertensive Drug Candesartan against Chronic Cerebral Ischemia in Rats.

12. Study of Candesartan Cilexetil: 2-Hydroxypropyl-β-Cyclodextrin Interactions: A Computational Approach Using Steered Molecular Dynamics Simulations.

13. Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial.

14. Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential.

15. Candesartan ameliorates vascular smooth muscle cell proliferation via regulating miR-301b/STAT3 axis.

16. Simultaneous quantification of candesartan and irbesartan in rabbit eye tissues by liquid chromatography-tandem mass spectrometry.

17. Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.

18. Quantitative bio-analysis of pitavastatin and candesartan in rat plasma by HPLC-UV: Assessment of pharmacokinetic drug-drug interaction.

19. Candesartan modulates microglia activation and polarization via NF-κB signaling pathway.

20. A simple, rapid and fully validated HPLC method for simultaneous quantitative bio-analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study.

21. Candesartan attenuates hypertension-associated pathophysiological alterations in the gut.

22. Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study.

23. Effects of Candesartan in the Acute Phase of Intracerebral Hemorrhage.

24. Preparation, characterization and ex vivo - in vivo assessment of candesartan cilexetil nanocrystals via solid dispersion technique using an alkaline esterase activator carrier.

25. Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma.

26. Candesartan in a rat model of testicular toxicity: New insight on its protective mechanism.

27. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.

28. Host-Guest Interactions between Candesartan and Its Prodrug Candesartan Cilexetil in Complex with 2-Hydroxypropyl-β-cyclodextrin: On the Biological Potency for Angiotensin II Antagonism.

29. Candesartan and epigallocatechin-3-gallate ameliorate gentamicin-induced renal damage in rats through p38-MAPK and NF-κB pathways.

30. A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension.

31. Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug.

32. Unique mode of binding between angiotensin II type 1 receptor and its blockers.

33. Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients.

34. Pleiotropic Benefits of the Angiotensin Receptor Blocker Candesartan in a Mouse Model of Alzheimer Disease.

35. No pharmacokinetic interactions between candesartan and amlodipine following multiple oral administrations in healthy subjects.

36. Formulation and In Vitro, In Vivo Correlation Between Two Candesartan Cilexetil Tablets.

37. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.

38. Antihypertensive drug-candesartan attenuates TRAIL resistance in human lung cancer via AMPK-mediated inhibition of autophagy flux.

39. Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats.

40. Candesartan ameliorates brain inflammation associated with Alzheimer's disease.

41. Candesartan, angiotensin II type 1 receptor blocker is able to relieve age-related cognitive impairment.

42. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.

43. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4 + T lymphocytes in Kazakh patients with hypertension from the Xinjiang region.

44. Noncholestatic acute hepatocellular injury following candesartan administration.

45. Pharmacokinetic and Bioequivalence Studies of a Newly Developed Branded Generic of Candesartan Cilexetil Tablets in Healthy Volunteers.

46. The simultaneous UPLC-MS/MS determination of emerging drug combination; candesartan and chlorthalidone in human plasma and its application.

47. The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension.

48. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.

49. Candesartan ameliorates arsenic-induced hypertensive vascular remodeling by regularizing angiotensin II and TGF-beta signaling in rats.

50. Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.

Catalog

Books, media, physical & digital resources